IN2014DN01822A - - Google Patents

Info

Publication number
IN2014DN01822A
IN2014DN01822A IN1822DEN2014A IN2014DN01822A IN 2014DN01822 A IN2014DN01822 A IN 2014DN01822A IN 1822DEN2014 A IN1822DEN2014 A IN 1822DEN2014A IN 2014DN01822 A IN2014DN01822 A IN 2014DN01822A
Authority
IN
India
Prior art keywords
relates
present
protease inhibitor
conjugates
conjugated
Prior art date
Application number
Other languages
English (en)
Inventor
Colin Watts
Sander Van Kasteren
Original Assignee
Univ Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dundee filed Critical Univ Dundee
Publication of IN2014DN01822A publication Critical patent/IN2014DN01822A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8142—Aspartate protease (E.C. 3.4.23) inhibitors, e.g. HIV protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN1822DEN2014 2011-08-15 2012-08-15 IN2014DN01822A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1114017.5A GB201114017D0 (en) 2011-08-15 2011-08-15 Inhibitors against endosomal/ysosomal enzymes
PCT/GB2012/000660 WO2013024243A1 (en) 2011-08-15 2012-08-15 Inhibitors against endosomal/lysosomal enzymes

Publications (1)

Publication Number Publication Date
IN2014DN01822A true IN2014DN01822A (enExample) 2015-05-15

Family

ID=44764498

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1822DEN2014 IN2014DN01822A (enExample) 2011-08-15 2012-08-15

Country Status (6)

Country Link
US (1) US9050374B2 (enExample)
EP (1) EP2744821B1 (enExample)
CN (1) CN103814046B (enExample)
GB (1) GB201114017D0 (enExample)
IN (1) IN2014DN01822A (enExample)
WO (1) WO2013024243A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10870115B2 (en) 2015-08-13 2020-12-22 Dyax Corp. Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
TN2019000032A1 (en) 2016-08-11 2020-07-15 Intrabio Ltd Pharmaceutical compositions and uses directed to lysosomal storage disorders
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323063A1 (en) * 1998-03-26 1999-09-30 University Of Dundee Use of inhibitors of mammalian asparaginyl endopeptidase for therapy of autoimmune disease
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease

Also Published As

Publication number Publication date
EP2744821A1 (en) 2014-06-25
CN103814046B (zh) 2017-05-17
EP2744821B1 (en) 2016-12-07
US9050374B2 (en) 2015-06-09
WO2013024243A1 (en) 2013-02-21
US20140308318A1 (en) 2014-10-16
GB201114017D0 (en) 2011-09-28
CN103814046A (zh) 2014-05-21

Similar Documents

Publication Publication Date Title
MX356282B (es) Composiciones y metodos que comprenden variantes de proteasa.
SG195196A1 (en) Dual targeting
PH12013500386A1 (en) Pesticidal compositions
BR112012025645A2 (pt) glicanos de alta manose.
PH12013500360B1 (en) Pesticidal compositions
BR112013007362A2 (pt) composição farmacêutica
GB201103836D0 (en) Conjugation process
BR112014001219A2 (pt) perfume
IL227682A0 (en) Compounds suppressing 17-il and γ- ifn, preparations containing them and their uses
UA114655C2 (uk) Піридин-2-аміди, придатні як агоністи канабіноїдного рецептора 2
MY161868A (en) Anti-bv8 antibodies and uses thereof
EP2632895A4 (en) HIV PROTEASE INHIBITORS
MX2015006915A (es) Preparacion de una bebida estable.
IN2014CN02318A (enExample)
CL2009001973S1 (es) Mostrador.
UA112760C2 (uk) Теобромін у комбінації з гвайфенезином для лікування кашлю
MX2015006616A (es) Doble direccion.
IN2014DN01822A (enExample)
WO2014052713A3 (en) Her2-and vegf-a-binding proteins with enhanced stability
EA201391563A1 (ru) Твердое вещество полихлоропрен с тиксотропными свойствами
BR112013032223A2 (pt) molécula de ácido nucleico isolada, e, composição
PT2306995E (pt) Propriedades antitumorais de inibidores de protease não modidficados
IN2014DN00168A (enExample)
UA94339C2 (ru) применение корвитина в качестве средства фригопротекторного действия
TN2011000372A1 (fr) جهاز مراقبة وتحكم في استهلاك المياه